Table 1Submitted for Review

Item Description
Drug productDostarlimab (Jemperli), 500 mg/10 mL vial (50 mg/mL)
Submitted priceDostarlimab, 50 mg/mL, single-use vial: $10,270.00 per 500 mg vial
IndicationMonotherapy for the treatment of adults with dMMR or MSI-H recurrent or advanced endometrial cancer that has progressed on or after prior treatment with a platinum-containing regimen
Health Canada approval statusNOC/c
Health Canada review pathwayAdvance consideration under NOC/c
NOC dateDecember 23, 2021
Reimbursement requestAs per indication
SponsorGlaxoSmithKline Inc.
Submission historyPreviously reviewed: No

dMMR = deficient mismatch repair; MSI-H = microsatellite instability-high; NOC = Notice of Compliance; NOC/c = Notice of Compliance with conditions.

From: Pharmacoeconomic Review

Cover of Dostarlimab (Jemperli)
Dostarlimab (Jemperli): CADTH Reimbursement Review: Therapeutic area: Endometrial cancer [Internet].
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.